Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Bio-Techne Corporation

NASDAQ

Market Cap.

12.73B

Avg. Volume

1.13M

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Bio-Techne Corporation!

Still processing it, give me a bit more time...

Bio-Techne Corporation News

Bio-Techne Corporation Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Website screenshot
HealthcareBiotechnology
bio-techne.com

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Bio-Techne Corporation Earnings & Revenue

Bio-Techne Corporation Financials

Table Compare

Compare TECH metrics with:

   

Earnings & Growth

TECH

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

TECH

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

TECH

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

TECH

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Bio-Techne Corporation Income

Bio-Techne Corporation Balance Sheet

Bio-Techne Corporation Cash Flow

Bio-Techne Corporation Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquityBuy
Return on AssetsStrong Buy
Debt/Equity RatioNeutral
Price/Earnings RatioStrong Buy
Price/Book RatioStrong Buy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Bio-Techne Corporation Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

0.3200

Payment DateDividendFrequency
2024-05-240.08Quarterly
2024-02-260.08Quarterly
2023-11-240.08Quarterly
2023-09-010.08Quarterly
2023-05-260.08Quarterly

Historical Market Cap

Shares Outstanding

Bio-Techne Corporation Executives

NameRole
Mr. Charles R. KummethSenior Advisor & Director
Mr. Kim KeldermanChief Executive Officer, President & Director
Mr. Robert M. GavinVice President of Corporate Development
Mr. James T. HippelExecutive Vice President of Finance & Chief Financial Officer
Mr. William A. GeistPresident of Protein Sciences Segment
NameRoleGenderDate of BirthPay
Mr. Charles R. KummethSenior Advisor & DirectorMale19601.26M
Mr. Kim KeldermanChief Executive Officer, President & DirectorMale1968845.71K
Mr. Robert M. GavinVice President of Corporate DevelopmentMale1968724.51K
Mr. James T. HippelExecutive Vice President of Finance & Chief Financial OfficerMale1971691.78K
Mr. William A. GeistPresident of Protein Sciences SegmentMale1970533.67K

Bio-Techne Corporation Insider Trades

Date14 May
NameHIGGINS JOHN L
RoleDirector
TransactionAcquired
TypeM-Exempt
Shares4000
Date14 May
NameHIGGINS JOHN L
RoleDirector
TransactionDisposed
TypeS-Sale
Shares4000
Date14 May
NameHIGGINS JOHN L
RoleDirector
TransactionDisposed
TypeM-Exempt
Shares4000
Date1 May
NameKlimovsky Judith V
RoleDirector
TransactionAcquired
TypeA-Award
Shares680
Date1 May
NameKlimovsky Judith V
RoleDirector
TransactionAcquired
TypeA-Award
Shares1610
DateNameRoleTransactionTypeShares
14 MayHIGGINS JOHN LDirectorAcquiredM-Exempt4000
14 MayHIGGINS JOHN LDirectorDisposedS-Sale4000
14 MayHIGGINS JOHN LDirectorDisposedM-Exempt4000
1 MayKlimovsky Judith VDirectorAcquiredA-Award680
1 MayKlimovsky Judith VDirectorAcquiredA-Award1610

Discover More

Streamlined Academy

Bio-Techne Corporation

NASDAQ

Market Cap.

12.73B

Avg. Volume

1.13M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Bio-Techne Corporation News

Bio-Techne Corporation Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Bio-Techne Corporation Earnings & Revenue

Bio-Techne Corporation Income

Bio-Techne Corporation Balance Sheet

Bio-Techne Corporation Cash Flow

Bio-Techne Corporation Financials Over Time

Bio-Techne Corporation Executives

NameRole
Mr. Charles R. KummethSenior Advisor & Director
Mr. Kim KeldermanChief Executive Officer, President & Director
Mr. Robert M. GavinVice President of Corporate Development
Mr. James T. HippelExecutive Vice President of Finance & Chief Financial Officer
Mr. William A. GeistPresident of Protein Sciences Segment
NameRoleGenderDate of BirthPay
Mr. Charles R. KummethSenior Advisor & DirectorMale19601.26M
Mr. Kim KeldermanChief Executive Officer, President & DirectorMale1968845.71K
Mr. Robert M. GavinVice President of Corporate DevelopmentMale1968724.51K
Mr. James T. HippelExecutive Vice President of Finance & Chief Financial OfficerMale1971691.78K
Mr. William A. GeistPresident of Protein Sciences SegmentMale1970533.67K

Bio-Techne Corporation Insider Trades

Date14 May
NameHIGGINS JOHN L
RoleDirector
TransactionAcquired
TypeM-Exempt
Shares4000
Date14 May
NameHIGGINS JOHN L
RoleDirector
TransactionDisposed
TypeS-Sale
Shares4000
Date14 May
NameHIGGINS JOHN L
RoleDirector
TransactionDisposed
TypeM-Exempt
Shares4000
Date1 May
NameKlimovsky Judith V
RoleDirector
TransactionAcquired
TypeA-Award
Shares680
Date1 May
NameKlimovsky Judith V
RoleDirector
TransactionAcquired
TypeA-Award
Shares1610
DateNameRoleTransactionTypeShares
14 MayHIGGINS JOHN LDirectorAcquiredM-Exempt4000
14 MayHIGGINS JOHN LDirectorDisposedS-Sale4000
14 MayHIGGINS JOHN LDirectorDisposedM-Exempt4000
1 MayKlimovsky Judith VDirectorAcquiredA-Award680
1 MayKlimovsky Judith VDirectorAcquiredA-Award1610

Streamlined Academy

Website screenshot
HealthcareBiotechnology
bio-techne.com

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Bio-Techne Corporation!

Still processing it, give me a bit more time...

Bio-Techne Corporation Financials

Table Compare

Compare TECH metrics with:

   

Earnings & Growth

TECH

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

TECH

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

TECH

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

TECH

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Bio-Techne Corporation Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

0.3200

Payment DateDividendFrequency
2024-05-240.08Quarterly
2024-02-260.08Quarterly
2023-11-240.08Quarterly
2023-09-010.08Quarterly
2023-05-260.08Quarterly

Bio-Techne Corporation Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquityBuy
Return on AssetsStrong Buy
Debt/Equity RatioNeutral
Price/Earnings RatioStrong Buy
Price/Book RatioStrong Buy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More